Diagnostic kit for the in vitro detection of antibodies to human immunodeficiency viruses (HIV1, HIV2 and HIV0) in serum and plasma by enzyme immunoassay.
Detectable antibodies appear in human blood approximately after two-three weeks of infection and stay there during life time. Thus, the presence of anti HIV antibodies in human blood is a marker for HIV infection.
 

Anti-HIV1/2 REC^™ was developed for detection of antibodies against HIV1 and/or HIV2 antigens in human serum and plasma in order to recognize the infected blood and plasma units and exclude them from use.

Evaluation of Anti-HIV1/2 REC^™  has performed by testing more than 4000 random blood samples from different area in Iran and other regions of the world including Africa.

Anti-HIV1/2 REC^™ screening kit is intended for the detection of human anti HIV1, HIV2 and HIV0 antibodies in serum or plasma

PRINCIPLE OF THE TEST

The  Anti-HIV1/2 REC^™ is an indirect solid phase enzyme immunoassay. Highly purified E. coli

derived proteins (gp36 AND P24-41) mimicking the immunoreactive fragments of HIV1GAG- gp41

and HIV2 gp36 encoded protein are bound to the surface of polystyrene plates and used as solid

phase. Peroxidase-conjugated monoclonal anti human IgG antibody (conjugate) is used as a

marker reagent.

The HIV1 sensitivity is 100 % for anti-HIV1 antibody positive serum samples. The HIV2 sensitivity is   100 % for HIV2 positive samples.

The specificity is 99.82% on a European blood donor population, patients with auto immune diseases, pregnant women, patients with other viral diseases and patients with parasitic infections from Central Africa.